Calliditas Therapeutics AB (publ) (CALT) Income Statement Analysis

See more : Bloomage BioTechnology Corporation Limited (688363.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Calliditas Therapeutics AB (publ) (CALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calliditas Therapeutics AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Calliditas Therapeutics AB (publ) (CALT)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.calliditas.se

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	1.21B	802.88M	229.35M	874.00K	184.83M	0.00	0.00	497.00K	478.00K
Cost of Revenue	77.06M	15.20M	0.00	0.00	0.00	51.00K	51.00K	56.52M	51.39M
Gross Profit	1.13B	787.68M	229.35M	874.00K	184.83M	-51.00K	-51.00K	-56.02M	-50.91M
Gross Profit Ratio	93.62%	98.11%	100.00%	100.00%	100.00%	0.00%	0.00%	-11,271.63%	-10,650.84%
Research & Development	499.54M	414.75M	357.49M	241.37M	149.83M	99.26M	384.00K	40.28M	36.89M
General & Administrative	332.99M	259.47M	210.63M	102.76M	62.88M	133.15M	84.60M	56.41M	51.28M
Selling & Marketing	727.74M	515.19M	179.60M	38.96M	0.00	0.00	0.00	0.00	0.00
SG&A	1.01B	774.66M	390.23M	141.72M	62.88M	133.15M	84.60M	56.41M	51.28M
Other Expenses	0.00	20.21M	6.09M	0.00	0.00	51.00K	51.00K	112.00K	111.00K
Operating Expenses	1.51B	1.21B	753.80M	383.10M	212.71M	133.20M	84.65M	56.52M	51.39M
Cost & Expenses	1.59B	1.22B	753.80M	383.10M	212.71M	133.20M	84.65M	56.52M	51.39M
Interest Income	29.10M	50.20M	102.00K	547.00K	926.00K	6.00K	0.00	2.00K	0.00
Interest Expense	73.20M	12.53M	7.11M	393.00K	325.00K	8.00K	2.24M	1.01M	9.00K
Depreciation & Amortization	16.59M	12.91M	34.43M	2.82M	1.82M	51.00K	51.00K	112.00K	111.00K
EBITDA	-367.80M	-388.82M	-483.94M	-379.40M	-25.13M	-133.14M	-84.60M	-56.40M	-51.28M
EBITDA Ratio	-30.48%	-52.55%	-228.67%	-43,346.80%	-13.60%	0.00%	0.00%	-11,348.69%	-10,727.62%
Operating Income	-384.40M	-421.94M	-524.46M	-379.72M	-28.02M	-132.48M	-84.51M	-56.02M	-50.91M
Operating Income Ratio	-31.85%	-52.55%	-228.67%	-43,446.22%	-15.16%	0.00%	0.00%	-11,271.63%	-10,650.84%
Total Other Income/Expenses	-72.62M	5.39M	9.47M	-53.93M	-4.48M	1.15M	-2.29M	-395.00K	375.00K
Income Before Tax	-457.02M	-409.42M	-513.37M	-436.15M	-32.50M	-132.05M	-86.79M	-56.91M	-51.01M
Income Before Tax Ratio	-37.87%	-50.99%	-223.84%	-49,902.86%	-17.58%	0.00%	0.00%	-11,451.11%	-10,672.38%
Income Tax Expense	9.17M	2.85M	-3.84M	360.00K	77.00K	441.00K	2.24M	1.01M	9.00K
Net Income	-466.19M	-412.27M	-509.54M	-436.51M	-32.58M	-132.05M	-86.79M	-56.91M	-51.01M
Net Income Ratio	-38.63%	-51.35%	-222.17%	-49,944.05%	-17.63%	0.00%	0.00%	-11,451.11%	-10,672.38%
EPS	-8.69	-7.78	-10.02	-9.73	-0.88	-5.09	-5.81	-1.71	-1.54
EPS Diluted	-8.69	-7.78	-10.02	-9.73	-0.88	-5.09	-5.81	-1.71	-1.54
Weighted Avg Shares Out	53.67M	53.02M	50.83M	44.87M	36.94M	25.95M	14.93M	33.23M	33.23M
Weighted Avg Shares Out (Dil)	53.67M	53.02M	50.83M	44.87M	36.94M	25.95M	14.93M	33.23M	33.23M

Calliditas Expects EMA's CHMP Opinion For Nefecon In Q2

March 22, 2022benzinga.com

Calliditas Therapeutics AB (NASDAQ: CALT) says that the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) can be expected in Q2 of 2022. In its review of the marketing authorization application (MAA) for...

5 Biotech Stocks For Your Late December 2021 Watchlist

December 16, 2021stockmarket.com

Should investors be treating these top biotech stocks as top picks in the stock market now?

Calliditas' (CALT) Tarpeyo Wins FDA Approval for Renal Disease

December 16, 2021zacks.com

Calliditas (CALT) obtains accelerated approval for Tarpeyo to reduce proteinuria in IgA nephropathy in the United States.

Calliditas Therapeutics: Q3 Earnings Insights

November 18, 2021benzinga.com

Calliditas Therapeutics (NASDAQ:CALT) reported its Q3 earnings results on Thursday, November 18, 2021 at 01:00 AM. Here's what investors need to know about the announcement.

Calliditas announces acquisition of remaining Genkyotex minority shares

October 7, 2021prnewswire.com

STOCKHOLM, Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100% of the share capital of Genkyotex SA ("Genkyotex"), after the completion of a centralized squeeze out offer to...

Is a Surprise Coming for Calliditas (CALT) This Earnings Season?

August 10, 2021zacks.com

Calliditas (CALT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Calliditas Receives FDA Fast Track Designation for setanaxib in PBC

August 9, 2021prnewswire.com

STOCKHOLM, Aug. 9, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for its lead NOX inhibitor candidate setanaxib for the...

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

July 21, 2021prnewswire.com

STOCKHOLM and BAD VILBEL, Germany, July 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas") and STADA Arzneimittel AG ("STADA") announced today that they have entered into a license agreement to register and commercialize a novel...

Calliditas secures $75 million term loan facility

July 15, 2021prnewswire.com

STOCKHOLM, July 15, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed a loan agreement of up to the Euro equivalent of $75 million with Kreos Capital. Proceeds from the...